Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rating Upgraded by Wall Street Zen

Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research firms have also commented on ORIC. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday. Piper Sandler began coverage on Oric Pharmaceuticals in a research note on Wednesday, January 7th. They set an “overweight” rating and a $22.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. JPMorgan Chase & Co. raised their price target on Oric Pharmaceuticals from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Finally, Evercore started coverage on Oric Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $25.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oric Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $20.20.

Oric Pharmaceuticals Trading Down 0.4%

Shares of NASDAQ ORIC opened at $13.45 on Friday. The stock’s 50-day moving average is $10.39 and its 200 day moving average is $11.00. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -8.85 and a beta of 1.35. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. On average, analysts forecast that Oric Pharmaceuticals will post -2.17 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jacob Chacko sold 33,374 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total transaction of $302,368.44. Following the completion of the transaction, the chief executive officer owned 581,711 shares in the company, valued at $5,270,301.66. This represents a 5.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dominic Piscitelli sold 52,000 shares of the business’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at approximately $920,679.48. The trade was a 43.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 106,814 shares of company stock valued at $1,199,135. Company insiders own 6.82% of the company’s stock.

Hedge Funds Weigh In On Oric Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Oric Pharmaceuticals by 48.8% in the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after buying an additional 1,525,445 shares during the period. Alkeon Capital Management LLC raised its position in shares of Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock worth $45,717,000 after acquiring an additional 500,000 shares in the last quarter. State Street Corp lifted its stake in shares of Oric Pharmaceuticals by 77.1% in the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after purchasing an additional 1,854,458 shares during the period. Orbimed Advisors LLC lifted its stake in shares of Oric Pharmaceuticals by 305.0% in the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after purchasing an additional 2,742,475 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Oric Pharmaceuticals by 14.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company’s stock valued at $26,955,000 after purchasing an additional 423,795 shares in the last quarter. 95.05% of the stock is owned by institutional investors.

Key Headlines Impacting Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised quarterly and FY2026 EPS estimates, narrowed the FY loss forecast (to ($1.28) from ($1.52)), kept a “Buy” rating and raised its price target to $25 — a material analyst upgrade supporting upside. Read More.
• Positive Sentiment: Oric reported a Q4 earnings beat (EPS -$0.30 vs. -$0.34 consensus), which acted as a near-term catalyst and likely drove recent buying interest. Read More.
• Positive Sentiment: Multiple broker actions (Wedbush Outperform; Piper Sandler, JPMorgan and others with overweight/buy calls and higher targets) have created a bullish analyst consensus — Zacks highlights the mean price target implying ~58% upside, which can attract momentum buyers. Read More.
• Neutral Sentiment: Consensus still shows multi-quarter losses (current full‑year consensus ~($2.17) per share), so the stock’s upside depends on continued clinical progress, margin improvement and execution. Read More.
• Neutral Sentiment: Institutional ownership is very high (~95%); while this can stabilize the stock, it may also limit new institutional inflows unless conviction strengthens. Read More.
• Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares (~$702.5k at ~$13.51), cutting his stake by ~43% — insider selling can be perceived negatively and may temper the rally. SEC Form 4: Read More.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.